A family history of prostate cancer can substantially increase a man’s probability of developing the disease, particularly when a father, brother or son was affected, several relatives have prostate cancer, or diagnoses occurred at younger ages. Some families carry inherited pathogenic variants such as BRCA2, HOXB13, ATM or mismatch-repair genes, but most men with a family history do not have a known single-gene syndrome. The clinical value of family history is therefore not to predict that cancer is inevitable; it is to recognize higher baseline risk, consider earlier PSA-based detection, and identify families in whom genetic counseling may be appropriate.
Having a first-degree relative with prostate cancer—especially a father or brother—roughly doubles or more than doubles relative risk in large studies. Risk increases further when several close relatives are affected, when cancer was diagnosed before about age 60, or when aggressive, metastatic or lethal prostate cancer clusters in a family. Both the mother’s and father’s sides matter because cancer-predisposition variants can be inherited from either parent.
01Which Family History Patterns Increase Prostate Cancer Risk Most?
First-degree relatives carry the strongest routinely collected signal
A first-degree relative is a:
- father;
- brother;
- or son.
Large epidemiological studies consistently show higher prostate-cancer risk in men with an affected first-degree relative.
The American Cancer Society summarizes this relationship by stating that having a father or brother with prostate cancer more than doubles a man’s risk compared with men without that family history.
National Cancer Institute reviews similarly describe approximately two- to threefold relative-risk increases in many studied populations.
One relative and several relatives do not carry the same implication
Family-history risk becomes stronger as the pattern becomes more concentrated.
Features that raise concern include:
- two or more first-degree relatives with prostate cancer;
- prostate cancer affecting several generations;
- multiple brothers with prostate cancer;
- both a father and brother affected;
- diagnosis before age 60;
- metastatic prostate cancer in a close relative;
- or a relative who died from prostate cancer at a relatively young age.
Why does age at diagnosis matter?
Prostate cancer becomes increasingly common with aging.
A diagnosis at age 85 can therefore carry a different hereditary signal from a diagnosis at age 48.
When several relatives develop prostate cancer unusually early, the probability of inherited susceptibility becomes more important because ordinary age-associated incidence is less able to explain the family pattern.
Does a brother matter more than a father?
Some epidemiological studies have reported particularly strong associations when a brother is affected.
Possible reasons include:
- brothers sharing more similar generations of environmental exposure;
- greater likelihood of comparable PSA-testing practices;
- shared inherited variants;
- and statistical differences between study populations.
Clinically, both father and brother history are important.
The more useful questions are:
- how many relatives were affected;
- how closely they are related;
- how young they were at diagnosis;
- and whether the disease was aggressive.
Does prostate cancer on the mother’s side count?
Yes.
This is one of the most important practical points in family-history assessment.
A man receives half of his inherited DNA from his mother. Pathogenic variants associated with prostate cancer can therefore travel through the maternal side even though female relatives do not have a prostate.
A maternal family history may reveal itself through:
- breast cancer;
- ovarian cancer;
- pancreatic cancer;
- colorectal or endometrial cancer in Lynch syndrome families;
- or prostate cancer in maternal uncles and grandfathers.
What if only one elderly relative had prostate cancer?
That history still matters, but its hereditary signal is generally weaker than a family containing:
- multiple affected relatives;
- young-onset disease;
- aggressive or metastatic disease;
- or several cancers associated with the same inherited syndrome.
Because prostate cancer is common in older men, some families will contain one late-life prostate-cancer diagnosis by chance rather than because of a strong inherited mutation.
Family history changes probability, not certainty. A man with several affected relatives may never develop prostate cancer, while a man with no known family history still can. Family history is used to adjust risk and testing strategy—not to make the diagnosis.
02What Does “Hereditary Prostate Cancer” Mean?
Familial and hereditary prostate cancer are related but not identical concepts
The word familial describes prostate cancer that clusters within a family more often than expected.
That clustering can reflect:
- shared genes;
- many common genetic variants;
- shared environment;
- similar health behaviors;
- similar PSA-testing patterns;
- or combinations of these factors.
The term hereditary prostate cancer is generally used when the pattern strongly suggests inherited genetic susceptibility, particularly across multiple close relatives or generations and when disease occurs at unusually young ages.
Most prostate cancer is not explained by one inherited mutation
This distinction prevents an important misunderstanding.
Even though prostate cancer has a strong heritable component at the population level, most individual prostate cancers are not caused by one identifiable high-penetrance germline variant.
Some families instead carry the combined effects of many lower-impact genetic variants.
What is a germline variant?
A germline variant is a genetic change present from conception and therefore found throughout the body’s cells.
It can potentially be passed to children.
This differs from a somatic tumor mutation, which develops within the cancer and is not necessarily present in the rest of the body or inherited by relatives.
Why does that distinction matter?
A germline pathogenic variant can have implications for:
- the patient’s prostate-cancer risk;
- risk of other cancers;
- screening strategies;
- treatment selection in some advanced cancers;
- and cancer risk among relatives.
A tumor-only mutation may affect treatment but may not imply inherited family risk unless follow-up germline testing confirms it.
How are inherited predisposition variants passed through a family?
Many well-recognized hereditary cancer predisposition syndromes relevant to prostate cancer follow an autosomal dominant inheritance pattern.
If one parent carries such a germline pathogenic variant, each child generally has a 50% chance of inheriting that variant.
That does not mean each child has a 50% chance of developing prostate cancer.
Inheritance of the variant and development of the cancer are different probabilities because penetrance is incomplete.
What does penetrance mean?
Penetrance describes the proportion of people carrying a particular pathogenic variant who eventually develop the associated disease.
A highly penetrant variant produces disease in a larger proportion of carriers. A lower-penetrance variant raises risk without causing disease in most carriers.
Penetrance can also depend on:
- age;
- sex;
- ancestry;
- other genes;
- and environmental or biological modifiers.
Hereditary does not mean inevitable. The presence of a germline pathogenic variant can substantially increase risk, but the correct statement is “higher susceptibility,” not “this person will develop prostate cancer.”
03Which Inherited Genes Are Linked to Prostate Cancer?
BRCA2 is one of the most clinically important prostate-cancer susceptibility genes
BRCA2 is involved in homologous-recombination DNA repair.
A pathogenic germline BRCA2 variant increases prostate-cancer susceptibility and is associated with a greater likelihood of clinically aggressive disease compared with non-carriers.
EAU evidence summaries estimate an overall prostate-cancer relative-risk range of roughly 2.5 to 4.6 for BRCA2 carriers, with larger relative effects reported for early-onset prostate cancer in some studies.
The exact absolute risk depends on:
- age;
- specific variant;
- family history;
- ancestry;
- and competing health risks.
What about BRCA1?
BRCA1 can also be associated with prostate-cancer susceptibility, but the association is generally less pronounced than for BRCA2.
A BRCA-family history becomes particularly relevant when prostate cancer occurs alongside:
- breast cancer;
- ovarian cancer;
- male breast cancer;
- or pancreatic cancer.
What is HOXB13?
HOXB13 is involved in prostate development and function.
The rare G84E variant is strongly associated with hereditary prostate-cancer susceptibility, particularly in men of Northern European ancestry.
National Cancer Institute reviews report several-fold increases in relative risk, but the magnitude varies with:
- family history;
- age;
- geography;
- and ancestry.
What are ATM, CHEK2 and other DNA-repair genes?
Prostate-cancer susceptibility also overlaps with genes involved in the cell’s response to DNA damage.
These include:
- ATM;
- CHEK2;
- PALB2 in selected contexts;
- and other homologous-recombination repair genes.
Not every pathogenic variant in these genes carries the same magnitude of prostate-cancer risk.
How does Lynch syndrome relate to prostate cancer?
Lynch syndrome is caused by germline pathogenic variants in mismatch-repair genes such as:
- MSH2;
- MLH1;
- MSH6;
- and PMS2.
These families are best known for increased colorectal and endometrial cancer risk, but prostate-cancer susceptibility is also increased in several mismatch-repair syndromes.
The magnitude is gene-specific rather than identical across all Lynch syndrome carriers.
Does one gene explain all hereditary prostate cancer?
No.
Hereditary susceptibility is genetically heterogeneous.
A family with strong clustering may have:
- a high-impact pathogenic variant;
- several moderate-risk variants;
- a high polygenic risk;
- or no currently identifiable genetic cause despite a convincing family pattern.
Can genetic testing come back negative even when the family pattern looks hereditary?
Yes.
A negative multigene panel does not prove that the family has no inherited susceptibility.
Possible explanations include:
- risk from genes not included or not yet discovered;
- polygenic susceptibility from many common variants;
- a pathogenic variant the test cannot detect;
- or familial clustering caused by a mixture of inherited and non-genetic factors.
A family history remains clinically relevant even when no pathogenic variant is found. Genetic testing can explain some hereditary families, but it does not replace the information contained in the pedigree itself.
04How Should Family History Affect PSA Screening and Genetic Counseling?
Higher inherited risk can justify earlier PSA discussion
Because early prostate cancer is often asymptomatic, family history is most useful before symptoms develop.
Current EAU guidance recommends offering informed PSA-based early detection from approximately:
- age 50 for men without additional recognized risk factors;
- age 45 for men with a family history of prostate cancer diagnosed before age 60;
- age 45 for men of African descent;
- and age 40 for carriers of pathogenic BRCA2 variants.
These ages are starting points for an informed discussion, not guarantees that yearly PSA testing is appropriate for every man.
Family history changes pre-test probability
Suppose two men have the same PSA result.
One has:
- no known prostate-cancer family history;
- a previously stable PSA;
- and no additional major risk features.
The other has:
- a father diagnosed at 52;
- two brothers with prostate cancer;
- and a maternal family history of breast and pancreatic cancer.
The laboratory PSA concentration may be identical, but the second man’s pre-test probability is higher.
That difference can affect how quickly clinicians move to:
- repeat PSA;
- PSA density;
- risk calculators;
- prostate MRI;
- or biopsy when appropriate.
Family history does not create a special PSA cutoff
There is no separate universal PSA threshold that automatically diagnoses cancer in men with a family history.
The same principles still apply:
- PSA is not cancer-specific;
- benign enlargement can raise PSA;
- prostatitis can raise PSA;
- prostate size matters;
- age matters;
- and MRI or biopsy decisions use combined risk.
For the biomarker itself, see PSA Testing.
Who should consider genetic counseling?
Genetic counseling is particularly relevant when the family includes patterns such as:
- several men with prostate cancer;
- prostate cancer diagnosed before age 60;
- metastatic prostate cancer;
- death from prostate cancer at a relatively young age;
- known BRCA or other pathogenic variants;
- male breast cancer;
- ovarian cancer;
- pancreatic cancer;
- or clusters of colorectal and endometrial cancer suggesting Lynch syndrome.
Why test an affected relative first when possible?
When a family contains several affected and unaffected members, testing an affected person first is often more informative.
If a pathogenic variant is identified in the person who developed cancer, other relatives can then undergo targeted testing for that specific family variant.
This is called cascade testing.
What does cascade testing tell relatives?
If a known family pathogenic variant exists:
- a relative who tests positive may need risk-specific counseling and surveillance;
- a relative who tests negative for that particular familial variant may avoid being managed as though he carries it;
- and female relatives may also require counseling depending on the gene because the same variant can influence breast, ovarian, pancreatic or other cancer risks.
Does germline testing matter after prostate cancer is diagnosed?
Yes, in selected patients.
The result can affect:
- risk information for relatives;
- screening strategies within the family;
- understanding of hereditary cancer susceptibility;
- and, for some men with advanced disease, treatment selection involving DNA-repair or immunotherapy pathways.
What is a variant of uncertain significance?
Genetic testing sometimes identifies a variant of uncertain significance (VUS).
This means the laboratory does not currently have enough evidence to classify the variant as either:
- pathogenic;
- or benign.
A VUS should generally not be treated as though a disease-causing mutation has been found.
Does a negative genetic test make someone average risk?
Not necessarily.
A man can have a strong prostate-cancer family history and a negative multigene panel.
His family history can still justify risk-adapted early detection because:
- not every inherited cause is known;
- polygenic risk may be important;
- and current testing does not explain every familial cluster.
What should someone bring to a genetic-counseling appointment?
Useful family information includes:
- which relatives had cancer;
- the exact cancer type;
- age at diagnosis;
- whether prostate cancer was localized or metastatic;
- age and cause of death when relevant;
- results of previous family genetic testing;
- and whether breast, ovarian, pancreatic, colorectal, uterine or other related cancers occurred.
Pathology reports or genetic-test reports from affected relatives can be especially useful when available.
A prostate-cancer pedigree can change over time. A man whose family history appeared unremarkable at age 40 may have a brother or uncle diagnosed later. Updating family history periodically can therefore change the appropriate early-detection strategy.
→How to Interpret Common Family-History Patterns
| Family pattern | What it suggests | What it does not prove | Possible clinical implication |
|---|---|---|---|
| One father diagnosed late in life | Meaningful first-degree family history. | A single-gene hereditary syndrome. | Consider risk-adapted PSA discussion according to age and guideline context. |
| Father diagnosed before 60 | Stronger hereditary signal than very late-onset disease. | That the son carries a pathogenic variant. | Earlier PSA discussion; review broader pedigree. |
| Two brothers with prostate cancer | Stronger familial clustering. | That cancer is inevitable for another brother. | Higher baseline risk; consider whether genetic counseling is appropriate. |
| Father + brother + grandfather | Multigenerational clustering compatible with hereditary susceptibility. | Which gene is responsible. | Detailed pedigree and possible germline evaluation. |
| Metastatic prostate cancer in close relative | Potentially important inherited-risk signal. | That all relatives will develop aggressive cancer. | Strengthens rationale for genetic assessment. |
| Prostate + breast + pancreatic cancers in family | Possible hereditary breast/ovarian cancer syndrome pattern. | BRCA2 without testing. | Genetic counseling may be particularly useful. |
| Prostate + colorectal + endometrial cancers | Can raise suspicion for Lynch syndrome depending on ages and family structure. | A mismatch-repair mutation. | Review Lynch criteria and consider genetics. |
| Known familial BRCA2 variant | Concrete inherited cancer-predisposition variant exists in family. | That an untested relative carries it. | Targeted genetic counseling/testing and earlier PSA strategy if positive. |
| Strong family history but negative gene panel | Familial risk can remain elevated. | That inherited susceptibility is absent. | Continue family-history-based risk assessment. |
| Variant of uncertain significance | Genetic change with insufficient classification evidence. | A pathogenic mutation. | Do not use as a positive hereditary-cancer result unless reclassified. |
?Common Questions About Hereditary Prostate Cancer
| Question | Practical answer |
|---|---|
| Is prostate cancer hereditary? | Some prostate cancer is strongly influenced by inherited susceptibility, but most cases are not explained by one known high-risk germline mutation. |
| Does prostate cancer run in families? | Yes. Family clustering is well established, particularly among first-degree relatives. |
| How much does a father with prostate cancer increase risk? | Large studies generally show around a twofold or greater relative-risk increase for a first-degree family history. |
| Does a brother with prostate cancer increase risk? | Yes. A brother is a first-degree relative, and some datasets show particularly strong familial associations between brothers. |
| What if both my father and brother had prostate cancer? | Multiple affected first-degree relatives create a stronger familial risk pattern than one affected relative. |
| Does it matter how old my relative was? | Yes. Younger age at diagnosis generally strengthens concern for inherited susceptibility. |
| Does prostate cancer on my mother’s side count? | Yes. Germline variants can be inherited from either parent. |
| Can my mother pass a prostate-cancer gene to me? | Yes. A mother can transmit variants such as BRCA2 even though she does not have a prostate. |
| Can a father pass BRCA2 to a daughter? | Yes. BRCA2 is not sex-limited in inheritance; sons and daughters can inherit the familial variant. |
| If a parent has a BRCA2 mutation, do all children inherit it? | No. For an autosomal dominant germline variant, each child generally has a 50% chance of inheriting the variant. |
| Does 50% inheritance mean 50% cancer risk? | No. The inheritance probability and cancer penetrance are different concepts. |
| What genes are linked to hereditary prostate cancer? | Important genes include BRCA2, BRCA1, HOXB13, ATM, CHEK2 and mismatch-repair genes associated with Lynch syndrome. |
| Is BRCA2 only a breast cancer gene? | No. BRCA2 is also an important prostate, pancreatic and other cancer-predisposition gene. |
| Does BRCA2 guarantee prostate cancer? | No. It raises susceptibility substantially but penetrance is incomplete. |
| What is HOXB13? | A gene involved in prostate development; certain pathogenic variants are associated with hereditary prostate-cancer risk. |
| Can Lynch syndrome involve prostate cancer? | Yes. Several mismatch-repair pathogenic variants associated with Lynch syndrome increase prostate-cancer susceptibility. |
| Should every man with prostate cancer have genetic testing? | Not necessarily. Eligibility depends on stage, pathology, family history, ancestry and guideline-specific criteria. |
| Should healthy men with family history get genetic testing? | Some should, particularly when the pedigree suggests an inherited cancer syndrome or a known familial pathogenic variant exists. |
| Should an affected relative be tested first? | When possible, yes. Finding a pathogenic variant in an affected relative can make testing other relatives much more informative. |
| What is cascade testing? | Targeted testing of relatives after a pathogenic germline variant has been identified in the family. |
| What if my genetic test is negative? | A negative panel does not erase a strong family history; inherited causes may remain unidentified. |
| What is a VUS? | A variant of uncertain significance is a genetic change whose disease relevance is not yet known. It should not be treated as a confirmed pathogenic result. |
| Does family history mean I need a prostate biopsy? | No. Family history changes baseline probability; biopsy decisions still depend on PSA, MRI and the complete clinical risk assessment. |
| When should PSA testing begin with family history? | EAU guidance supports informed PSA testing from about age 45 when a qualifying family history is present, with earlier discussion for BRCA2 carriers. |
| Can family history change over time? | Yes. Relatives can be diagnosed later, so periodic updates to the family history are useful. |
ΣSummary
- Family history is an established prostate-cancer risk factor.
- A father, brother or son is a first-degree relative.
- Having an affected first-degree relative roughly doubles or more than doubles relative risk in major epidemiological summaries.
- Risk generally increases as more close relatives are affected.
- Multiple affected generations strengthen the hereditary signal.
- Young age at diagnosis is particularly informative.
- Prostate cancer diagnosed before about age 60 raises more concern for inherited susceptibility than very late-onset disease.
- Metastatic or lethal prostate cancer in the family can strengthen concern for hereditary disease.
- Both maternal and paternal family histories matter.
- A mother can transmit prostate-cancer predisposition variants to her sons.
- Breast, ovarian and pancreatic cancers can provide clues to BRCA-associated familial risk.
- Colorectal and endometrial cancers can provide clues to Lynch syndrome.
- Familial prostate cancer means clustering within families.
- Familial clustering does not always mean one identifiable high-risk gene is responsible.
- Hereditary prostate cancer generally implies a stronger pattern of inherited susceptibility.
- A germline variant is present throughout the body and can potentially be passed to children.
- A somatic mutation develops within the tumor and is not automatically inherited.
- Many hereditary cancer predisposition genes follow autosomal dominant inheritance.
- If one parent carries such a variant, each child generally has a 50% chance of inheriting it.
- A 50% inheritance probability is not the same as a 50% chance of developing prostate cancer.
- Incomplete penetrance means some carriers never develop the associated cancer.
- BRCA2 is one of the most important hereditary prostate-cancer genes.
- EAU summaries estimate roughly 2.5- to 4.6-fold overall relative risk for BRCA2 carriers.
- BRCA2-associated prostate cancers are also more likely on average to show aggressive features.
- BRCA1 is also relevant but generally has a weaker prostate-cancer association than BRCA2.
- HOXB13 is strongly associated with hereditary prostate-cancer susceptibility in selected populations.
- ATM and CHEK2 are additional DNA-repair genes associated with inherited susceptibility.
- Lynch syndrome mismatch-repair genes can also increase prostate-cancer risk.
- No single gene explains all hereditary prostate cancer.
- A family can have a strong hereditary pattern despite negative multigene testing.
- Polygenic susceptibility can contribute to familial risk.
- Family history remains clinically meaningful even when no pathogenic variant is identified.
- Family history can justify earlier PSA-based early-detection discussions.
- EAU guidance supports informed PSA testing from about age 45 for men with qualifying family history.
- EAU guidance supports informed testing from about age 40 for BRCA2 carriers.
- Higher inherited risk does not create a special diagnostic PSA cutoff.
- PSA remains a probability marker rather than a cancer diagnosis.
- Family history changes the pre-test probability attached to a PSA result.
- An elevated PSA does not automatically require biopsy.
- Repeat PSA, PSA density, MRI and risk calculators can refine risk.
- Genetic counseling is useful when the family pattern suggests inherited cancer susceptibility.
- Testing an affected relative first is often the most informative strategy.
- A known pathogenic family variant allows targeted cascade testing of relatives.
- Female relatives may also be affected by the same hereditary cancer syndrome.
- A variant of uncertain significance is not the same as a pathogenic variant.
- A negative genetic result does not necessarily return someone with strong family history to average risk.
- Family histories should be updated because new diagnoses can change risk interpretation.
- Family history guides earlier attention; PSA, MRI and biopsy determine whether prostate cancer is actually present.
Clinical bottom line: hereditary prostate-cancer risk is identified from the pattern of disease across a family—not from one relative alone and not from one gene alone. The strongest clues are multiple close relatives, young diagnoses, aggressive disease and related hereditary-syndrome cancers. These findings can justify earlier PSA discussion and genetic counseling, but they do not diagnose cancer or make cancer inevitable.
Medical disclaimer: This article provides general education about family history and hereditary prostate cancer. It cannot calculate an individual’s genetic or lifetime risk. Germline testing can affect medical care and relatives, so test selection and interpretation should involve qualified clinicians or genetic counselors when appropriate. A family history or positive genetic result does not itself diagnose prostate cancer.
For the broader set of age, ancestry, inherited and lifestyle associations, see Prostate Cancer Risk Factors. For the full route from risk through PSA, MRI, biopsy, grading and treatment, return to the Prostate Cancer hub. For the biomarker used in risk-adapted early detection, see PSA Testing. The next guide examines BRCA1 and BRCA2 in prostate cancer, including inherited risk, aggressive disease, genetic testing and treatment implications.
Evidence Sources
- National Cancer Institute — Genetics of Prostate Cancer (PDQ): family history, hereditary prostate cancer, BRCA2, HOXB13, DNA-repair genes and germline testing.
- European Association of Urology — Prostate Cancer Epidemiology and Aetiology: familial risk, hereditary disease and inherited susceptibility.
- European Association of Urology — Prostate Cancer Diagnostic Evaluation: risk-adapted PSA testing, family history and germline testing recommendations.
- American Cancer Society — Prostate Cancer Risk Factors: family history and inherited gene changes.
- National Cancer Institute — The Genetics of Cancer: germline inheritance, pathogenic variants, penetrance and hereditary cancer syndromes.
